Anivive Repurposes Veterinary Drug GC376 for COVID-19 And Submits Pre-IND to FDA
LONG BEACH, Calif. -- May 26, 2020 -- Anivive Lifesciences, a biotechnology company focused on developing first-in-class therapeutics for veterinary patients, has filed a pre-Investigational New Drug (pIND) request with the Food and Drug...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Biotechnology | Clinical Trials | COVID-19 | Investigational New Drugs | Pharmaceuticals | Veterinary Research